James E Egan

University Of California At Davis

$455,570

Attributed

$1,822,280

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $659.1K · FY2023–25

$1M$750K$500K$250K$0

'23

'24

'25

Funding mix

By agency

NIH$1,822,280 · 1

By mechanism

R01$1,822,280 · 1

Top collaborators

Most similar at University Of California At Davis

Same institution · by research overlap

Others in their field

Other Rising Stars on “3-Dimensional”

Daofeng Li · Salk Institute For Biological Studies$9,887,266
Ons M'saad · Panluminate Inc.$4,058,447
Rebecca Bradford · American Type Culture Collection$3,862,721
Pei-Hsun Wu · Johns Hopkins University$3,570,953
Fang Liu · Massachusetts General Hospital$3,379,144
Ruben Dries · Boston Medical Center$3,371,645

Research focus

3-DimensionalAcidsAdvanced Pancreatic CancerAbraxaneAnimal ModelAntibody TherapyAnti-Cancer TherapeuticAnti-Pd-L1AffectAnti-Pd-L1 TherapyBiodistributionCaliforniaCancer ImmunotherapyCanis FamiliarisCd8-Positive T-LymphocytesCheckpoint InhibitionChemotherapyClinical DevelopmentClinically RelevantClinical ResearchClinical TranslationClinical TreatmentClinical TrialsCollaborations

Grant awards (5)

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$572,502

R01 · FY2025 · CA

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$86,583

R01 · FY2025 · CA

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$496,381

R01 · FY2024 · CA

TGX-1214 - Combination strategy for the treatment of advanced pancreatic cancer$83,743

R01 · FY2024 · CA

TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer$583,071

R01 · FY2023 · CA